Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov.

2.

The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep.

3.

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2018 Mar 13;9(2). pii: e00188-18. doi: 10.1128/mBio.00188-18. No abstract available.

4.

Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Maincent JP, Najvar LK, Kirkpatrick WR, Huang S, Patterson TF, Wiederhold NP, Peters JI, Williams RO 3rd.

Drug Dev Ind Pharm. 2017 Feb;43(2):264-274. doi: 10.1080/03639045.2016.1236811. Epub 2016 Oct 5.

5.

Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Kadosh D, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Wiederhold NP, Patterson TF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6703-6708. doi: 10.1128/AAC.01144-16. Print 2016 Nov.

6.

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5600-3. doi: 10.1128/AAC.00229-16. Print 2016 Sep.

7.

Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model.

White PL, Wiederhold NP, Loeffler J, Najvar LK, Melchers W, Herrera M, Bretagne S, Wickes B, Kirkpatrick WR, Barnes RA, Donnelly JP, Patterson TF.

J Clin Microbiol. 2016 Apr;54(4):960-6. doi: 10.1128/JCM.03233-15. Epub 2016 Jan 20.

8.

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2015 Jun 23;6(3):e00647. doi: 10.1128/mBio.00647-15. Erratum in: MBio. 2018 Mar 13;9(2):.

9.

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Matsumoto S, Bocanegra RA, Herrera ML, Wickes BL, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2015 May;59(5):2875-81. doi: 10.1128/AAC.04857-14. Epub 2015 Mar 9.

10.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

11.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

12.

Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis.

Jambunathan K, Watson DS, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF, Askew DS, Kodukula K, Galande AK.

Med Mycol. 2013 Aug;51(6):592-602. doi: 10.3109/13693786.2012.761360. Epub 2013 Jan 28.

PMID:
23356446
13.

Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients.

Westbrook SD, Kirkpatrick WR, Wiederhold NP, Freytes CO, Toro JJ, Patterson TF, Redding SW.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Mar;115(3):354-8. doi: 10.1016/j.oooo.2012.10.012. Epub 2013 Jan 9.

14.

Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF, Thornton CR.

J Clin Microbiol. 2013 Feb;51(2):459-65. doi: 10.1128/JCM.02142-12. Epub 2012 Nov 21.

15.

Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Sorrell TC, Patterson TF.

Antimicrob Agents Chemother. 2013 Feb;57(2):745-50. doi: 10.1128/AAC.01624-12. Epub 2012 Nov 19.

16.

The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy.

Patel PK, Erlandsen JE, Kirkpatrick WR, Berg DK, Westbrook SD, Louden C, Cornell JE, Thompson GR, Vallor AC, Wickes BL, Wiederhold NP, Redding SW, Patterson TF.

AIDS Res Treat. 2012;2012:262471. doi: 10.1155/2012/262471. Epub 2012 Aug 28.

17.

A murine model of Cryptococcus gattii meningoencephalitis.

Thompson GR 3rd, Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Graybill JR, Patterson TF.

J Antimicrob Chemother. 2012 Jun;67(6):1432-8. doi: 10.1093/jac/dks060. Epub 2012 Feb 29.

18.

Assessment of Aspergillus fumigatus in guinea pig bronchoalveolar lavages and pulmonary tissue by culture and realtime polymerase chain reaction studies.

Hooper DG, Bolton VE, Sutton JS, Guilford FT, Straus DC, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF.

Int J Mol Sci. 2012;13(1):726-36. doi: 10.3390/ijms13010726. Epub 2012 Jan 11.

19.

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.

Kirkpatrick WR, Najvar LK, Vallor AC, Wiederhold NP, Bocanegra R, Pfeiffer J, Perkins K, Kugler AR, Sweeney TD, Patterson TF.

J Antimicrob Chemother. 2012 Apr;67(4):970-6. doi: 10.1093/jac/dkr567. Epub 2012 Jan 11.

PMID:
22240402
20.

Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.

Lengerova M, Kocmanova I, Racil Z, Hrncirova K, Pospisilova S, Mayer J, Najvar LK, Wiederhold NP, Kirkpatrick WR, Patterson TF.

J Clin Microbiol. 2012 Mar;50(3):602-8. doi: 10.1128/JCM.05356-11. Epub 2011 Dec 21.

21.

Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Patterson TF.

Clin Microbiol Infect. 2012 Feb;18(2):E20-3. doi: 10.1111/j.1469-0691.2011.03712.x. Epub 2011 Nov 30.

22.

Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.

McCulloch E, Ramage G, Rajendran R, Lappin DF, Jones B, Warn P, Shrief R, Kirkpatrick WR, Patterson TF, Williams C.

J Clin Pathol. 2012 Jan;65(1):83-6. doi: 10.1136/jcp.2011.090464. Epub 2011 Nov 2.

PMID:
22049217
23.

Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF.

Antimicrob Agents Chemother. 2011 Jul;55(7):3254-60. doi: 10.1128/AAC.01750-10. Epub 2011 Apr 18.

24.

Recovery of Candida dubliniensis and other Candida species from the oral cavity of subjects with periodontitis who had well-controlled and poorly controlled type 2 diabetes: a pilot study.

Melton JJ, Redding SW, Kirkpatrick WR, Reasner CA, Ocampo GL, Venkatesh A, Mealey BL.

Spec Care Dentist. 2010 Nov-Dec;30(6):230-4. doi: 10.1111/j.1754-4505.2010.00159.x. Epub 2010 Oct 21.

PMID:
21044102
25.

Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.

Westbrook SD, Wiederhold NP, Vallor AC, Kotara S, Bernardo S, Lee SA, Kirkpatrick WR, Toro JJ, Freytes C, Patterson TF, Redding SW.

Med Mycol. 2010 May;48(3):557-60. doi: 10.3109/13693780903213504.

26.

Oropharyngeal candidiasis in the era of antiretroviral therapy.

Thompson GR 3rd, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, Redding SW, Patterson TF.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Apr;109(4):488-95. doi: 10.1016/j.tripleo.2009.11.026. Epub 2010 Feb 13. Review.

27.

Screening for drug-resistant Candida yeasts with chromogenic agar.

Kirkpatrick WR, Zimmerman JD, Haikal FP, Broker MJ, Brockway E, Fothergill AW, McCarthy DI, Patterson TF, Redding SW.

Med Mycol. 2010 Sep;48(6):807-16. doi: 10.3109/13693780903514542.

28.

Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis.

Wiederhold NP, Thornton CR, Najvar LK, Kirkpatrick WR, Bocanegra R, Patterson TF.

Clin Vaccine Immunol. 2009 Dec;16(12):1844-6. doi: 10.1128/CVI.00268-09. Epub 2009 Sep 30.

29.

Don't throw your blood clots away: use of blood clot may improve sensitivity of PCR diagnosis in invasive aspergillosis.

McCulloch E, Ramage G, Jones B, Warn P, Kirkpatrick WR, Patterson TF, Williams C.

J Clin Pathol. 2009 Jun;62(6):539-41. doi: 10.1136/jcp.2008.063321. Epub 2009 Feb 3.

PMID:
19190008
30.

Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2593-8. doi: 10.1128/AAC.00276-08. Epub 2008 May 12.

31.

Cell wall proteinaceous components in isolates of Candida albicans and non-albicans species from HIV-infected patients with oropharyngeal candidiasis.

López-Ribot JL, Kirkpatrick WR, McAtee RK, Revankar SG, Patterson TF.

Rev Iberoam Micol. 1998 Sep;15(3):125-30.

32.

Antifungal susceptibility testing of micafungin against Candida glabrata isolates.

Oliveira ER, Fothergill A, Kirkpatrick WR, Patterson TF, Redding SW.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):457-9. doi: 10.1016/j.tripleo.2007.12.003.

PMID:
18329581
33.

Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Vallor AC, Kirkpatrick WR, Bocanegra R, Molina D, Olivo M, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Mar;52(3):1176-8. Epub 2007 Dec 26.

34.

New guinea pig model of Cryptococcal meningitis.

Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill JR.

Antimicrob Agents Chemother. 2007 Aug;51(8):3011-3. Epub 2007 Jun 11.

35.

Candida krusei sepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient.

Westbrook SD, Kirkpatrick WR, Freytes CO, Toro JJ, Bernardo S, Patterson TF, Redding SW, Lee SA.

Med Mycol. 2007 Mar;45(2):187-90.

PMID:
17365656
36.

Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, Kirkpatrick WR, Bocanegra R, Vallor AC, Patterson TF, Filler SG.

Antimicrob Agents Chemother. 2006 Oct;50(10):3501-3.

37.

Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus.

Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR.

Eukaryot Cell. 2006 Jul;5(7):1091-103.

38.

Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.

Cramer RA Jr, Gamcsik MP, Brooking RM, Najvar LK, Kirkpatrick WR, Patterson TF, Balibar CJ, Graybill JR, Perfect JR, Abraham SN, Steinbach WJ.

Eukaryot Cell. 2006 Jun;5(6):972-80.

39.
40.

Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.

Kirkpatrick WR, Vallor AC, McAtee RK, Ryder NS, Fothergill AW, Rinaldi MG, Patterson TF.

Antimicrob Agents Chemother. 2005 Nov;49(11):4751-3.

41.

In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.

Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW.

Antimicrob Agents Chemother. 2005 Aug;49(8):3544-5.

42.

Comparison of DNA-based typing methods to assess genetic diversity and relatedness among Candida albicans clinical isolates.

López-Ribot JL, McAtee RK, Kirkpatrick WR, Perea S, Patterson TF.

Rev Iberoam Micol. 2000 Jun;17(2):49-54.

43.

Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.

Burn AK, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, McCarthy DI, Rinaldi MG, Redding SW.

J Clin Microbiol. 2004 Dec;42(12):5846-8.

44.

Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation.

Redding SW, Marr KA, Kirkpatrick WR, Coco BJ, Patterson TF.

Med Mycol. 2004 Oct;42(5):479-81.

PMID:
15552650
45.

The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis.

Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman J, Patterson TF, Martinez JP, López-Ribot JL.

FEMS Microbiol Lett. 2004 Mar 19;232(2):133-8.

46.

Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer.

Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, Rinaldi MG, Thomas CR Jr.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jan;97(1):47-52.

PMID:
14716255
47.

Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer.

Dahiya MC, Redding SW, Dahiya RS, Eng TY, Kirkpatrick WR, Coco BJ, Sadkowski LC, Fothergill AW, Waite A, Rinaldi MG, Patterson TF, Thomas CR.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):79-83.

PMID:
12909218
48.

Proteinase detection, DNA typing and antimycotic susceptibility of Candida isolates from Colombian women with vulvovaginal candidiasis.

Cardona-Castro N, Revankar SG, Ortiz P, Cuervo C, Kirkpatrick WR, McAtee RK, Patterson TF.

Rev Iberoam Micol. 2002 Jun;19(2):89-94.

49.

Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J.

J Clin Microbiol. 2003 Feb;41(2):619-22.

50.

Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.

Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF.

J Clin Microbiol. 2002 Sep;40(9):3135-9.

Supplemental Content

Loading ...
Support Center